Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter November 26, 2016

Benzyldimethyl[3-(miristoylamino)-propyl]ammonium chloride stabilized silver nanoparticles (Argumistin™) in medicine: results of clinical trials for treatment of infectious diseases of dogs and perspectives for humans

Yurii Krutyakov, Alexey Klimov, Boris Violin, Vladimir Kuzmin, Victoria Ryzhikh, Alexander Gusev, Olga Zakharova and George Lisichkin


Increased interest in nanosilver during the last 10 years is mainly explained by the emergence and spread of pathogenic microorganisms with multiple drug resistance, including resistance to last-generation antibiotics. In this article, we for the first time, give a description of large-scale clinical trials of a new nanosilver based antibacterial drug [containing two active components: silver nanoparticles (AgNPs) (10–50 ppm) and benzyldimethyl[3-(miristoylamino)-propyl]ammonium chloride (100 ppm)] registered in Russia in 2015 as a veterinary drug under the brand name Argumistin™. This drug has been approved for application in a diluted dosage form – as eye drops, intranasal drops and orally; it has also been approved for application in a more concentrated dosage form (up to 50 ppm of nanosilver) as ear drops and as an antiseptic during demodicosis and gum disease treatment, open wound treatment, etc. We have registered the high therapeutic effectiveness of Argumistin™ during treatment of infectious conjunctivitis, gingivitis, parodontosis and enteritis of dogs. Application of this antibacterial drug gives considerable (up to 70% in case of periodontal diseases) reduction in the treatment period and prevention of complications. The results of clinical trials in the treatment of infectious diseases of dogs makes Argumistin™ a promising candidate for an effective antibacterial drug for human medicine.


This article was not supported by grants.

  1. Conflict of interest statement: Authors state no conflict of interest. All authors have read the journal’s Publication ethics and publication malpractice statement available at the journal’s website and hereby confirm that they comply with all its parts applicable to the present scientific work.


1. Brennan S, Leaper D. The effect of antiseptics on the healing wound: a study using the rabbit ear chamber Br J Surg 1985;72:780–2.10.1002/bjs.1800721004Search in Google Scholar PubMed

2. Baggot J. Antimicrobial selection, administration and dosage. J South Afr Vet A 1998;69:174–85.10.4102/jsava.v69i4.849Search in Google Scholar PubMed

3. Ortuño A, Scorza V, Castellà J, Lappin M. Prevalence of intestinal parasites in shelter and hunting dogs in Catalonia, Northeastern Spain. Vet J 2014;199:465–7.10.1016/j.tvjl.2013.11.022Search in Google Scholar PubMed

4. Martins C, Barros C, Bier D, Marinho A, Figueiredo J, Hoffmann J, et al. Dog parasite incidence and risk factors, from sampling after one-year interval, in Pinhais. Brazil Rev Bras Parasitol Vet. 2012;21:101–6.10.1590/S1984-29612012000200006Search in Google Scholar

5. Berset-Istratescu C, Glardon O, Magouras I, Frey C, Gobeli S, Burgener I. Follow-up of 100 dogs with acute diarrhoea in a primary care practice. Vet J. 2014;199:188–90.10.1016/j.tvjl.2013.10.014Search in Google Scholar PubMed

6. Chatzopoulos D, Athanasiou L, Spyrou V, Fthenakis G, Billinis C. Rotavirus infections in domestic animals. J Hellenic Vet Med Soc 2013;64:145–60.10.12681/jhvms.15489Search in Google Scholar

7. Truszczyński M, Posyniak A, Pejsak Z. Mechanisms of the emergence of resistance against the action of antibiotics and disinfectants in bacteria. Med Wet 2013;69:131–5.Search in Google Scholar

8. Scott W. Antimicrobial resistance: time for action. Vet Rec 2011;169:122–3.10.1136/vr.d4784Search in Google Scholar PubMed

9. Samson-Himmelstjerna G, Blackhall W. Will technology provide solutions for drug resistance in veterinary helminths? Vet Parasitol 2005;132:22339.10.1016/j.vetpar.2005.07.014Search in Google Scholar PubMed

10. Morley P, Apley M, Besser T, Burney D, Fedorka-Cray P, Papich M, et al. Antimicrobial drug use in veterinary medicine. J Vet Int Med 2005;19:617–29.10.1111/j.1939-1676.2005.tb02739.xSearch in Google Scholar

11. Persoons D, Hoorebeke S, Hermans K, Butaye P, Kruif A, Haesebrouck F, et al. Methicillin-resistant Staphylococcus aureus in poultry. Emerg Infect Dis 2009;15:452–3.10.3201/eid1503.080696Search in Google Scholar PubMed PubMed Central

12. Krutyakov Yu, Kudrinskiy A, Olenin A, Lisichkin G. Synthesis and properties of silver nanoparticles: advances and prospects. Russ Chem Rev 2008;77:233–57.10.1070/RC2008v077n03ABEH003751Search in Google Scholar

13. Credé C. Die Verhütung der Augenentzündung der Neugeborenen (“Prevention of inflammatory eye disease in the newborn”). Arch Gynäkol 1881;17:50–3.Search in Google Scholar

14. Burrell R. A scientific perspective on the use of topical silver preparations. Ostomy Wound Manage 2003;49(5A Suppl):19–24.Search in Google Scholar

15. Klasen H. A Historical review of the use of silver in the treatment of burns. II. Renew Interest for silver. Burns 2000;26:131–8.10.1016/S0305-4179(99)00116-3Search in Google Scholar

16. Gupta A, Maynes M, Silver S. Effects of halides on plasmid-mediated silver resistance in Escherichia coli. Appl Environ Microbiol 1998;64:5042–5.10.1128/AEM.64.12.5042-5045.1998Search in Google Scholar

17. Matsumura Y, Yoshikata K, Kunisaki S, Tsuchido T. Mode of bactericidal action of silver zeolite and its comparison with that of silver nitrate. Appl Environ Microbiol 2003;69:4278–81.10.1128/AEM.69.7.4278-4281.2003Search in Google Scholar

18. Morones JR, Elecheguerra JL, Camacho A, Holt K, Kouri JB, Ramirez JT, et al. The bactericidal effect of silver nanoparticles. Nanotechnology 2005;16:2346–53.10.1088/0957-4484/16/10/059Search in Google Scholar

19. Raffi M, Hussain F, Bhatti TM, Akhter JI, Hameed A, Hasan MM. Antibacterial characterization of silver nanoparticles against E. coli ATCC-15224. J Mater Sci Technol 2008;24:192–6.Search in Google Scholar

20. De Souza A, Mehta D, Leavitt RW. Bactericidal activity of combinations of Silver-Water Dispersion™ with 19 antibiotics against seven microbial strains. Curr Sci 2006;91:926–9.Search in Google Scholar

21. Li P, Wu C, Wu Q, Li J. Synergetic antibacterial effects of b-lactam antibiotic combined with silver nanoparticles. Nanotechnology 2005;16:1912–17.10.1088/0957-4484/16/9/082Search in Google Scholar

22. Vertelov G, Krutyakov Yu, Efremenkova O, Olenin A, Lisichkin G. A versatile synthesis of a highly bactericidal Myramistin® stabilized silver nanoparticles. Nanotechnology 2008;19:1–7.10.1088/0957-4484/19/35/355707Search in Google Scholar

23. Bolyakhina SA, Nasartdinova GF, Donchenko NA, Korobkova EA, Denisov AN, Krutyakov YuA. Acute and chronic toxity of the veterinary drug Argumistin. Sib Bull Agric Sci 2014;3:95–101. (in Russian).Search in Google Scholar

24. Koptev VYu. Embriotoxicity and teratogenicity study of Argumistin preparation when administered orally. Study report. Novosibirsk 2014:12. (in Russian).Search in Google Scholar

25. Kuzmin VA. Immunotoxicity study of veterinary preparation Argumistin when consumed orally. Study report. Saint-Petersburg 2014:20. (in Russ.)Search in Google Scholar

26. Andreeva NL. Carcinogenity study of veterinary preparation Argumistin. Study report. Saint-Petersburg 2014:18. (in Russsian).Search in Google Scholar

27. Andreeva NL. Miramistin pharmacokinetics study in mice tissues and organs after oral administration of veterinary preparation Argumistin. Study report. Saint-Petersburg 2014:14. (in Russian).Search in Google Scholar

28. Andreeva NL. Miramistin residues evaluation in chicken tissues and organs after oral administration of veterinary preparation Argumistin. Study report. Saint-Petersburg 2014:13. (in Russian).Search in Google Scholar

29. Andreeva NL. Miramistin residues evaluation in cow milk, tissues and organs after intercisternal and intrauterine application of veterinary preparation Argumistin. Study report. Saint-Petersburg 2014:19. (in Russian).Search in Google Scholar

30. Demling RH, Leslie DeSanti MD. The rate of re-epithelialization across meshed skin grafts is increased with exposure to silver. Burns 2002;28:264–6.10.1016/S0305-4179(01)00119-XSearch in Google Scholar

31. Lansdown ABG, Silver 2: toxicity in mammals and how its products aid wound repair. J. Wound Care 2002;11:173–7.10.12968/jowc.2002.11.5.26398Search in Google Scholar PubMed

32. Lansdown ABG. Metallothioneins: potential therapeutic aids for wound healing in the skin. Wound Repair Regen 2002;10:130–2.10.1046/j.1524-475X.2002.20101.xSearch in Google Scholar PubMed

33. Nadworny PL, Wang J, Tredget EE, Burrell RE. Anti-inflammatory activity of nanocrystalline silver in a porcine contact dermatitis model. Naomed Nanotechnol Biol Med 2008;4:241–251.10.1016/j.nano.2008.04.006Search in Google Scholar PubMed

34. Bhol KC, Schechter PJ. Topical nanocrystalline silver cream suppresses inflammatory cytokines and induces apoptosis of inflammatory cells in a murine model of allergic contact dermatitis. Br J Dermatol 2005;152:1235–42.10.1111/j.1365-2133.2005.06575.xSearch in Google Scholar PubMed

35. Wright JB, Lam K, Buret AG, Olson ME, Burrell RE. Early healing events in a porcine model of contaminated wounds: effects of nanocrystalline silver on matrix metalloproteinases, cell apoptosis, and healing. Wound Repair Regen 2002;10:141–51.10.1046/j.1524-475X.2002.10308.xSearch in Google Scholar

Received: 2016-6-27
Accepted: 2016-10-18
Published Online: 2016-11-26
Published in Print: 2016-10-1

©2016 Walter de Gruyter GmbH, Berlin/Boston

Scroll Up Arrow